Topic: chronic lymphocytic leukemia
The biotech changed its plans because its phase 3 overall response rate data “were not sufficiently mature to conduct the analysis.”
Fred Hutchinson scientists have identified biomarkers associated with dangerous side effects possible in cancer patients treated with CAR-T cells.
Wednesday's shot of your news of note.
TG Therapeutics’ experimental med ublituximab used alongside AbbVie’s marketed Imbruvica (ibrutinib) has hit its primary endpoint in a phase 3 study in chronic lymphocytic leukemia (CLL) patients, as the company eyes an accelerated FDA approval later this year.
TG Therapeutics got orphan drug designation from the FDA for both its clinical candidates this week.